董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Juliet Tammenoms Bakker | 女 | Independent Director | 63 | 未披露 | 未持股 | 2025-12-18 |
| J. Andy Corley | 男 | Chairman of the Board | 69 | 12.00万美元 | 未持股 | 2025-12-18 |
| Robert Warner | 男 | Independent Director | 58 | 未披露 | 未持股 | 2025-12-18 |
| Ron Kurtz | 男 | Co-President, Chief Executive Officer and Director | 62 | 74.07万美元 | 未持股 | 2025-12-18 |
| Shweta Singh Maniar | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-18 |
| Tamara R. Fountain | -- | Independent Director | -- | 未披露 | 未持股 | 2025-12-18 |
| William J. Link | 男 | Independent Director | 79 | 未披露 | 未持股 | 2025-12-18 |
| Robert J. Palmisano | 男 | Independent Director | 80 | 未披露 | 未持股 | 2025-12-18 |
| Julie B. Andrews | 女 | Independent Director | 54 | 未披露 | 未持股 | 2025-12-18 |
| Raymond W. Cohen | 男 | Director | 66 | 未披露 | 未持股 | 2025-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Shelley Thunen | 女 | Co-President, Chief Financial Officer and Principal Accounting Officer | 72 | 69.96万美元 | 未持股 | 2025-12-18 |
| Ron Kurtz | 男 | Co-President, Chief Executive Officer and Director | 62 | 74.07万美元 | 未持股 | 2025-12-18 |
| Eric Weinberg | 男 | Chief Business Development Officer | 64 | 92.37万美元 | 未持股 | 2025-12-18 |
| Ilya Goldshleger | -- | Co-President and Chief Operating Officer | 50 | 154.44万美元 | 未持股 | 2025-12-18 |
| Scott Gaines | -- | Chief Customer Officer | -- | 未披露 | 未持股 | 2025-12-18 |
董事简历
中英对照 | 中文 | 英文- Juliet Tammenoms Bakker
-
Juliet Tammenoms Bakker自2018年3月起担任董事会成员，自2018年10月起担任薪酬委员会成员以及提名和公司治理委员会主席。自2007年1月以来，Tammenoms Bakker女士一直担任梦百合风险投资公司Longitude Capital Management Co.，LLC的董事总经理。Tammenoms Bakker女士拥有学士学位。他拥有康奈尔大学农业和生命科学学院的硕士学位和哈佛大学JohnF.Kennedy政府学院的硕士学位。
Juliet Tammenoms Bakker,co-founded Longitude Capital, a healthcare venture capital firm, where she has served as a Managing Director since 2006. Previously, Ms. Tammenoms Bakker served as a Managing Director of Pequot Ventures, a venture capital firm, where she founded the life sciences investment practice. Prior to Pequot Ventures, Ms. Tammenoms Bakker was an equity research analyst with Banque Paribas. Ms. Tammenoms Bakker currently serves on the board of directors of RxSight, Inc. and on the boards of directors of multiple privately held healthcare companies. Ms. Tammenoms Bakker previously served on the boards of directors of various other publicly traded companies, including Eargo, Inc., Axonics Modulation Technologies, Inc., and Venus Concept Inc. Ms. Tammenoms Bakker received an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University. - Juliet Tammenoms Bakker自2018年3月起担任董事会成员，自2018年10月起担任薪酬委员会成员以及提名和公司治理委员会主席。自2007年1月以来，Tammenoms Bakker女士一直担任梦百合风险投资公司Longitude Capital Management Co.，LLC的董事总经理。Tammenoms Bakker女士拥有学士学位。他拥有康奈尔大学农业和生命科学学院的硕士学位和哈佛大学JohnF.Kennedy政府学院的硕士学位。
- Juliet Tammenoms Bakker,co-founded Longitude Capital, a healthcare venture capital firm, where she has served as a Managing Director since 2006. Previously, Ms. Tammenoms Bakker served as a Managing Director of Pequot Ventures, a venture capital firm, where she founded the life sciences investment practice. Prior to Pequot Ventures, Ms. Tammenoms Bakker was an equity research analyst with Banque Paribas. Ms. Tammenoms Bakker currently serves on the board of directors of RxSight, Inc. and on the boards of directors of multiple privately held healthcare companies. Ms. Tammenoms Bakker previously served on the boards of directors of various other publicly traded companies, including Eargo, Inc., Axonics Modulation Technologies, Inc., and Venus Concept Inc. Ms. Tammenoms Bakker received an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University.
- J. Andy Corley
-
J.Andy Corley自2015年1月起担任董事会成员。Corley先生自2012年以来还担任NeuroLens，Inc.的董事会成员，在那里他目前担任董事会主席，并自2016年以来担任Flying L Partners的合伙人。Corley先生于1998年联合创立Eyeonics，Inc.，并担任其首席执行官和董事会主席，直到2008年2月该公司被出售给Bausch&Lomb，Inc.。2008年至2011年，Corley先生在Bausch&Lomb收购Eyeonics，Inc.后担任外科部门总裁。1987年，Corley先生还联合创立了Chiron Vision Corp.，这是一家专注于LASIK开发的公司，并担任屈光手术部门的总经理直到1997年12月。Corley先生获得Georgia Southern University工商管理学士学位。
J. Andy Corley has served as a member of board of directors since January 2015. Mr. Corley has also served as a board member of Neurolenses, Inc. since 2012 where he currently serves as Chairman of the Board, and has been a partner at Flying L Partners since 2016. Mr. Corley co-founded eyeonics, Inc. in 1998 and served as its Chief Executive Officer and Chairman of the Board until the company was sold to Bausch & Lomb, Inc. in February 2008. Mr. Corley then served as President of the Surgical Division at Bausch & Lomb following its acquisition of eyeonics, Inc from 2008 to 2011. Mr. Corley also co-founded Chiron Vision Corp., a company focused on the development of LASIK, in 1987 and served as General Manager of the Refractive Surgery Division until December 1997. Mr. Corley received a Bachelor of Business Administration degree from Georgia Southern University. - J.Andy Corley自2015年1月起担任董事会成员。Corley先生自2012年以来还担任NeuroLens，Inc.的董事会成员，在那里他目前担任董事会主席，并自2016年以来担任Flying L Partners的合伙人。Corley先生于1998年联合创立Eyeonics，Inc.，并担任其首席执行官和董事会主席，直到2008年2月该公司被出售给Bausch&Lomb，Inc.。2008年至2011年，Corley先生在Bausch&Lomb收购Eyeonics，Inc.后担任外科部门总裁。1987年，Corley先生还联合创立了Chiron Vision Corp.，这是一家专注于LASIK开发的公司，并担任屈光手术部门的总经理直到1997年12月。Corley先生获得Georgia Southern University工商管理学士学位。
- J. Andy Corley has served as a member of board of directors since January 2015. Mr. Corley has also served as a board member of Neurolenses, Inc. since 2012 where he currently serves as Chairman of the Board, and has been a partner at Flying L Partners since 2016. Mr. Corley co-founded eyeonics, Inc. in 1998 and served as its Chief Executive Officer and Chairman of the Board until the company was sold to Bausch & Lomb, Inc. in February 2008. Mr. Corley then served as President of the Surgical Division at Bausch & Lomb following its acquisition of eyeonics, Inc from 2008 to 2011. Mr. Corley also co-founded Chiron Vision Corp., a company focused on the development of LASIK, in 1987 and served as General Manager of the Refractive Surgery Division until December 1997. Mr. Corley received a Bachelor of Business Administration degree from Georgia Southern University.
- Robert Warner
-
Robert Warner已被提名加入我们的董事会，与本次发行结束同时生效，届时他还将担任薪酬委员会和公司治理与提名委员会的成员。Warner先生于2015年8月至2018年2月担任爱尔康视觉护理专营权爱尔康的总裁兼总经理。在此之前，Warner先生从2012年1月到2015年7月担任爱尔康美国和加拿大总裁，从2010年11月到2012年1月担任爱尔康加拿大和拉丁美洲总裁。从2005年1月到2010年10月，Warner先生在爱尔康公司担任越来越多的责任职位。沃纳先生是爱尔康公司执行领导团队的成员超过10年，并领导爱尔康公司从雀巢公司向诺华公司的多数股权过渡。Warner先生目前在两家私人医疗设备公司I Lumen Scientific和Eyeyon Medical的董事会任职（担任后者的董事长），也是Grace，The Grapevine Relief and Community Exchange的董事会成员。Warner先生拥有佩斯大学化学学士学位和罗格斯大学工商管理硕士学位。
Robert Warner has been nominated to join board of directors, effective concurrent with the closing of this offering, at which time he will also serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. Mr. Warner served as President and General Manager of Alcon Vision Care Franchise Alcon from August 2015 until February 2018. Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010 Mr. Warner served in increasing positions of responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i Lumen Scientific and EyeYon Medical (serving as Chairman for the latter), and is also a board member of GRACE, the Grapevine Relief and Community Exchange. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University. - Robert Warner已被提名加入我们的董事会，与本次发行结束同时生效，届时他还将担任薪酬委员会和公司治理与提名委员会的成员。Warner先生于2015年8月至2018年2月担任爱尔康视觉护理专营权爱尔康的总裁兼总经理。在此之前，Warner先生从2012年1月到2015年7月担任爱尔康美国和加拿大总裁，从2010年11月到2012年1月担任爱尔康加拿大和拉丁美洲总裁。从2005年1月到2010年10月，Warner先生在爱尔康公司担任越来越多的责任职位。沃纳先生是爱尔康公司执行领导团队的成员超过10年，并领导爱尔康公司从雀巢公司向诺华公司的多数股权过渡。Warner先生目前在两家私人医疗设备公司I Lumen Scientific和Eyeyon Medical的董事会任职（担任后者的董事长），也是Grace，The Grapevine Relief and Community Exchange的董事会成员。Warner先生拥有佩斯大学化学学士学位和罗格斯大学工商管理硕士学位。
- Robert Warner has been nominated to join board of directors, effective concurrent with the closing of this offering, at which time he will also serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. Mr. Warner served as President and General Manager of Alcon Vision Care Franchise Alcon from August 2015 until February 2018. Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010 Mr. Warner served in increasing positions of responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i Lumen Scientific and EyeYon Medical (serving as Chairman for the latter), and is also a board member of GRACE, the Grapevine Relief and Community Exchange. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University.
- Ron Kurtz
-
Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego. - Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
- Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.
- Shweta Singh Maniar
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Tamara R. Fountain
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- William J. Link
-
William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University. - William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
- William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University.
- Robert J. Palmisano
-
Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College. - Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
- Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College.
- Julie B. Andrews
-
Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW. - Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
- Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW.
- Raymond W. Cohen
-
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University. - Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen,Prior to joining Kestra as a director, from 2013 to late 2024, Mr. Cohen served as the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, which was sold to Boston Scientific Corporation (NYSE: BSX) in November 2024. From 2023 to 2025, Mr. Cohen served as the chairman of the board of directors of SoniVie Ltd until it was acquired by Boston Scientific Corporation in March 2025. Mr. Cohen currently serves as chairman of the boards of directors of the privately held companies Nalu Medical Inc. and Archimedes Vascular, vice chairman of the board of directors of the privately held company Tulavi Medical, and a member of the board of directors of the private equity sponsor-backed company Spectrum Vascular. Previously, Mr. Cohen served as chairman of the board of directors of BioLife Solutions Inc. (Nasdaq: BLFS) and as a director of Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI). Mr. Cohen received his B.S. in Business Management from Binghamton University.
高管简历
中英对照 | 中文 | 英文- Shelley Thunen
Shelley Thunen自2015年7月以来一直担任我们的董事会成员。Thunen女士自2016年1月起担任医疗器械公司RxSight，Inc.的首席行政官兼首席财务官。2013年1月至2015年10月，Thunen女士担任医疗设备公司Endologix Inc.的首席财务官兼公司秘书。2010年8月至2012年12月，Thunen女士担任Lensx，Inc.的副总经理，这是Alcon，Inc.的间接全资子公司，Alcon，Inc.是视力护理产品的开发商和制造商，Novartis International AG于2011年4月收购了该公司。2008年4月至2010年8月，Thunen女士担任Lensx，Inc.的董事会成员兼审计委员会主席，2009年11月至2010年8月，Thunen女士担任Lensx，Inc.的首席财务官兼Vice President，该公司于2010年8月被Alcon，Inc.收购。在Lensx，Inc.之前，Thunen女士在公共和私人医疗设备公司担任过各种管理和执行职务。Thunen女士在加州大学欧文分校（University of California，Irvine）获得经济学学士学位和工商管理硕士学位。
Shelley Thunen joined RxSight, Inc. in January 2016 as Chief Administrative Officer and has served as Chief Financial Officer since February 2017. From January 2013 to October 2015 Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. From August 2010 to December 2012 Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. Prior to the Alcon acquisition of LenSx, Inc. in August 2010 she served as a board member and chair of the audit committee from April 2008 to August 2010 as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. in April 2007. Ms. Thunen served on the board of directors of eyeonics, Inc. from June 2007 to February 2008 and as a board member and chair of the audit committee of Restoration Robotics, Inc. Nasdaq: HAIR from July 2015 to November 2019 prior to its acquisition by Venus Concept Inc. (Nasdaq: VERO) She also has served as a board member and audit committee chair of Surface Ophthalmics, Inc since August 2020. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine.- Shelley Thunen自2015年7月以来一直担任我们的董事会成员。Thunen女士自2016年1月起担任医疗器械公司RxSight，Inc.的首席行政官兼首席财务官。2013年1月至2015年10月，Thunen女士担任医疗设备公司Endologix Inc.的首席财务官兼公司秘书。2010年8月至2012年12月，Thunen女士担任Lensx，Inc.的副总经理，这是Alcon，Inc.的间接全资子公司，Alcon，Inc.是视力护理产品的开发商和制造商，Novartis International AG于2011年4月收购了该公司。2008年4月至2010年8月，Thunen女士担任Lensx，Inc.的董事会成员兼审计委员会主席，2009年11月至2010年8月，Thunen女士担任Lensx，Inc.的首席财务官兼Vice President，该公司于2010年8月被Alcon，Inc.收购。在Lensx，Inc.之前，Thunen女士在公共和私人医疗设备公司担任过各种管理和执行职务。Thunen女士在加州大学欧文分校（University of California，Irvine）获得经济学学士学位和工商管理硕士学位。
- Shelley Thunen joined RxSight, Inc. in January 2016 as Chief Administrative Officer and has served as Chief Financial Officer since February 2017. From January 2013 to October 2015 Ms. Thunen served as the Chief Financial Officer of Endologix, Inc. From August 2010 to December 2012 Ms. Thunen served as Associate General Manager of Alcon LenSx, Inc. Prior to the Alcon acquisition of LenSx, Inc. in August 2010 she served as a board member and chair of the audit committee from April 2008 to August 2010 as well as Chief Financial Officer and Vice President, Operations from November 2009 to August 2010. Ms. Thunen joined IntraLase Corp. in May 2001 and was its Chief Financial Officer and later Executive Vice President & Chief Financial Officer until its acquisition by Advanced Medical Optics, Inc. in April 2007. Ms. Thunen served on the board of directors of eyeonics, Inc. from June 2007 to February 2008 and as a board member and chair of the audit committee of Restoration Robotics, Inc. Nasdaq: HAIR from July 2015 to November 2019 prior to its acquisition by Venus Concept Inc. (Nasdaq: VERO) She also has served as a board member and audit committee chair of Surface Ophthalmics, Inc since August 2020. Ms. Thunen received a B.A. in economics and an M.B.A. from the University of California, Irvine.
- Ron Kurtz
Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.- Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
- Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.
- Eric Weinberg
Eric Weinberg自2015年6月起担任我们的首席商务官。在加入RXSight之前，他是LensX Lasers，Inc.的联合创始人，从2008年7月到2010年8月担任首席商务官，在其被AlconInc.收购之前。2010年8月至2014年4月，他担任Alcon Lensx，Inc.外科开发副总裁。他于1999年9月加入Intralase Corp.，担任销售副总裁，后来担任全球营销高级副总裁，直到2007年4月公司被Advanced Medical Optics，Inc.收购。1993年3月至1997年10月被Bausch&Lomb，Inc.收购，Weinberg先生担任Chiron Vision Corp.屈光外科全球总监。他继续担任Bausch&Lomb的全球屈光外科主任直到1999年8月。1980年，温伯格在施坦威仪器公司（Steinway Instruments）开始了他的医疗器械职业生涯。
Eric Weinberg has served as Chief Commercial Officer since June 2015. Prior to joining RxSight, he was a co-founder of LenSx Lasers, Inc. and served as Chief Commercial Officer from July 2008 to August 2010 prior to its acquisition by Alcon Inc. He went on to serve as Vice President of Surgical Development at Alcon LenSx, Inc. from August 2010 to April 2014. He joined IntraLase Corp. in September 1999 as Vice President of Sales and later as the Senior Vice President, Global Marketing until the company was acquired by Advanced Medical Optics, Inc. in April 2007. Mr. Weinberg served as Global Director of Refractive Surgery at Chiron Vision Corp. from March 1993 until October 1997 when it was acquired by Bausch & Lomb, Inc. He continued as Global Director of Refractive Surgery at Bausch & Lomb until August 1999. Mr. Weinberg began his career in medical devices at Steinway Instruments in 1980.- Eric Weinberg自2015年6月起担任我们的首席商务官。在加入RXSight之前，他是LensX Lasers，Inc.的联合创始人，从2008年7月到2010年8月担任首席商务官，在其被AlconInc.收购之前。2010年8月至2014年4月，他担任Alcon Lensx，Inc.外科开发副总裁。他于1999年9月加入Intralase Corp.，担任销售副总裁，后来担任全球营销高级副总裁，直到2007年4月公司被Advanced Medical Optics，Inc.收购。1993年3月至1997年10月被Bausch&Lomb，Inc.收购，Weinberg先生担任Chiron Vision Corp.屈光外科全球总监。他继续担任Bausch&Lomb的全球屈光外科主任直到1999年8月。1980年，温伯格在施坦威仪器公司（Steinway Instruments）开始了他的医疗器械职业生涯。
- Eric Weinberg has served as Chief Commercial Officer since June 2015. Prior to joining RxSight, he was a co-founder of LenSx Lasers, Inc. and served as Chief Commercial Officer from July 2008 to August 2010 prior to its acquisition by Alcon Inc. He went on to serve as Vice President of Surgical Development at Alcon LenSx, Inc. from August 2010 to April 2014. He joined IntraLase Corp. in September 1999 as Vice President of Sales and later as the Senior Vice President, Global Marketing until the company was acquired by Advanced Medical Optics, Inc. in April 2007. Mr. Weinberg served as Global Director of Refractive Surgery at Chiron Vision Corp. from March 1993 until October 1997 when it was acquired by Bausch & Lomb, Inc. He continued as Global Director of Refractive Surgery at Bausch & Lomb until August 1999. Mr. Weinberg began his career in medical devices at Steinway Instruments in 1980.
- Ilya Goldshleger
Ilya Goldshleger加入RXSight，Inc.，担任工程副总裁，自2019年6月起担任我们的首席运营官。Goldshleger博士于2015年9月加入RXSight，担任工程副总裁，负责LAL和LDD系统及其附件的开发和工程。在加入RXSight之前，Goldshleger博士从2010年到2015年在Alcon LensX，Inc.担任多个管理职位，最后担任研发光学和诊断总监，从2008年10月到2010年8月被Alcon，Inc.收购，在LensX Lasers，Inc.担任多个研究与开发职位。Goldshleger博士在莫斯科物理和技术学院获得物理和数学科学硕士学位，在俄罗斯科学院获得化学物理博士学位。
Ilya Goldshleger joined RxSight, Inc. as the Vice President, Engineering and has served as Chief Operating Officer since June 2019. Dr. Goldshleger joined RxSight in September 2015 as the Vice President of Engineering and was responsible for the development and engineering of the LAL and LDD system and its accessories. Prior to joining RxSight, Dr. Goldshleger held various management roles at Alcon LenSx, Inc. from 2010 to 2015 last serving as Director, R&D Optics and Diagnostics, and held various roles in research and development at LenSx Lasers, Inc. from October 2008 to its acquisition by Alcon, Inc. in August 2010. Dr. Goldshleger received a Master of Science in Physics and Mathematics from the Moscow Institute of Physics and Technology and a Ph.D. in Chemical Physics from the Russian Academy of Sciences.- Ilya Goldshleger加入RXSight，Inc.，担任工程副总裁，自2019年6月起担任我们的首席运营官。Goldshleger博士于2015年9月加入RXSight，担任工程副总裁，负责LAL和LDD系统及其附件的开发和工程。在加入RXSight之前，Goldshleger博士从2010年到2015年在Alcon LensX，Inc.担任多个管理职位，最后担任研发光学和诊断总监，从2008年10月到2010年8月被Alcon，Inc.收购，在LensX Lasers，Inc.担任多个研究与开发职位。Goldshleger博士在莫斯科物理和技术学院获得物理和数学科学硕士学位，在俄罗斯科学院获得化学物理博士学位。
- Ilya Goldshleger joined RxSight, Inc. as the Vice President, Engineering and has served as Chief Operating Officer since June 2019. Dr. Goldshleger joined RxSight in September 2015 as the Vice President of Engineering and was responsible for the development and engineering of the LAL and LDD system and its accessories. Prior to joining RxSight, Dr. Goldshleger held various management roles at Alcon LenSx, Inc. from 2010 to 2015 last serving as Director, R&D Optics and Diagnostics, and held various roles in research and development at LenSx Lasers, Inc. from October 2008 to its acquisition by Alcon, Inc. in August 2010. Dr. Goldshleger received a Master of Science in Physics and Mathematics from the Moscow Institute of Physics and Technology and a Ph.D. in Chemical Physics from the Russian Academy of Sciences.
- Scott Gaines
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介